Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/31939
Title: | Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score | Authors: | Kunchok, Amy Lechner-Scott, Jeannette Granella, Franco Trojano, Maria Alroughani, Raed Sola, Patrizia Ferraro, Diana Lugaresi, Alessandra Onofrj, Marco Ozakbas, Serkan Izquierdo, Guillermo Grammond, Pierre Luis Sanchez-Menoyo, Jose VAN WIJMEERSCH, Bart Boz, Cavit Pucci, Eugenio McCombe, Pamela Grand'Maison, Francois Spitaleri, Daniele Vucic, Steve Hupperts, Raymond Jokubaitis, Vilija Sormani, Maria Pia Butzkueven, Helmut Kalincik, Tomas |
Issue Date: | 2021 | Publisher: | SAGE PUBLICATIONS LTD | Source: | MULTIPLE SCLEROSIS JOURNAL, 27(5), p. 695-705 | Abstract: | Background: The magnetic resonance imaging in multiple sclerosis (MAGNIMS) score combines relapses and magnetic resonance imaging (MRI) lesions to predict disability outcomes in relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta. Objective: To validate the MAGNIMS score and extend to other disease-modifying therapies (DMTs). To examine the prognostic value of gadolinium contrast-enhancing (Gd+) lesions. Methods: This RRMS MSBase cohort study (n = 2293) used a Cox model to examine the prognostic value of relapses, MRI activity and the MAGNIMS score for disability worsening during treatment with interferon-beta and three other DMTs. Results: Three new T2 lesions (hazard ratio (HR) = 1.60,p = 0.028) or two relapses (HR = 2.24,p = 0.002) on interferon-beta (for 12 months) were predictive of disability worsening over 4 years. MAGNIMS score = 2 (1 relapse and > 3 T2 lesions or > 2 relapses) was associated with a greater risk of disability worsening on interferon-beta (HR = 2.0,p = 0.001). In pooled cohort of four DMTs, similar associations were seen (MAGNIMS score = 2: HR = 1.72,p = 0.001). Secondary analyses demonstrated that the addition of Gd+ to the MAGNIMS did not materially improve its prediction of disability worsening. Conclusion: We have validated the MAGNIMS score in RRMS and extended its application to three other DMTs: 1 relapse and > 3 T2 lesions or > 2 relapses predicted worsening of disability. Contrast-enhancing lesions did not substantially improve the prognostic score. | Notes: | Kalincik, T (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, CORe, 300 Grattan St,L4 East, Melbourne, Vic 3051, Australia. tomas.kalincik@unimelb.edu.au |
Other: | Kalincik, T (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, CORe, 300 Grattan St,L4 East, Melbourne, Vic 3051, Australia. tomas.kalincik@unimelb.edu.au | Keywords: | Multiple sclerosis;therapy;prediction;magnetic resonance imaging;outcomes;prognosis | Document URI: | http://hdl.handle.net/1942/31939 | ISSN: | 1352-4585 | e-ISSN: | 1477-0970 | DOI: | 10.1177/1352458520936823 | ISI #: | WOS:000546608300001 | Rights: | 2020 by SAGE Publications | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
amy.pdf Restricted Access | Published version | 572.03 kB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
7
checked on Apr 14, 2024
Page view(s)
40
checked on Sep 7, 2022
Download(s)
42
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.